. ppGpp downregulates DNA replication, transcription, translation, and various metabolic pathways 3, 4, 8 . These changes help bacteria enter a dormant state that enables them to survive starvation, stress, and antibiotics. ppGpp is also critical for biofilm formation and the virulence of many pathogens 9, 10 . Despite its central importance in bacterial physiology and nearly five decades of study, precisely how (p)ppGpp regulates cell growth remains incompletely understood because the full set of effector proteins is unknown. Over the years, ~25 E. coli proteins have been reported to bind or be inhibited by ppGpp in vitro (Supplementary Table 1 ). However, the physiological relevance of these targets remains largely untested, with the exception of RNA polymerase (RNAP) (Fig. 1a) . ppGpp binds RNAP at two sites, thereby suppressing the expression of rRNA and ribosomal-protein genes (Fig. 1a) while also activating some genes involved in amino-acid synthesis 11, 12 . A more comprehensive identification of ppGpp targets is needed to fully understand the physiological effects of ppGpp on E. coli and other bacteria. Two recent studies have used differentialradial-capillary-action-of-ligand-assays (DRaCALAs) to screen for (p)ppGpp effectors 13, 14 . This assay measures the mobility of radiolabeled ppGpp on nitrocellulose filters treated with lysate from cells overproducing a single protein and thus requires laborious construction of overexpression libraries. As a nonequilibrium assay, DRaCALA also probably misses targets with fast off rates. The application of DRaCALA to Staphylococcus aureus identified seven targets, including five GTPases involved in ribosome bio genesis 14 . For E. coli, this method identified 12 putative new targets and 9 known ppGpp-binding proteins, but missed 11 others that bind ppGpp in vitro, underscoring that assay's high false-negative rate 13 . Here, we designed and synthesized ppGpp-peptide conjugates for the covalent capture of ppGpp-binding proteins in cell lysates with subsequent identification by mass spectrometry. Our systematic approach identified 56 hits from E. coli, including almost all previously characterized effectors. We validated the new proteins identified and then focused on one, PurF, which catalyzes the committed step of de novo purine synthesis. Structural, biochemical, and genetic analyses indicated that the inhibition of ATP and GTP synthesis through PurF is an important but largely overlooked aspect of ppGpp-based growth control. More generally, our development of ppGpp capture compounds provides a global view of how ppGpp controls growth and candidate effectors for future study.
IPTG inhibited the growth of both strains on LB agar plates in a dose-dependent manner, though less effectively for the RNAP 1 -2 -strain than the WT control (Fig. 1b) . The inhibition was ppGpp dependent because expression of the catalytically inactive RelA′ D275G mutant had no detectable effect on growth.
The difference in IPTG sensitivity may indicate that the RNAP 1 - 
2
-strain grows better than the WT after ppGpp accumulation. Alternatively, it may reflect a difference in RelA′ levels in the two strains. In agreement with the latter possibility, we found that when grown in M9GAV (M9 + glucose + amino acids + vitamins), a synthetic rich medium ( Supplementary Fig. 1b ), the RNAP 1 - 
-strain produced less RelA′ protein ( Supplementary Fig. 1c ) and less cytoplasmic ppGpp than the WT strain at the same concentration of IPTG (Fig. 1c) . To circumvent this complication, we adjusted the IPTG dosage so that the postinduction ppGpp levels would be approximately equal for the two strains, reaching 1 nmol per optical density at 600 nm (OD 600 ), or ~1.5 mM in the cytoplasm, after 30 min (Fig. 1c) . Strikingly, under these conditions, the growth of both strains was similarly inhibited after inducing RelA′ (Fig. 1d) , thus indicating that ppGpp can arrest cell growth through effectors other than RNAP.
Design and synthesis of photo-cross-linkable ppGpp analogs. To understand how ppGpp regulates growth independently of RNA polymerase, we sought to systematically identify the protein effectors of ppGpp by covalently capturing these effectors via photocross-linking chemistry 16 . We designed a series of 'cross-linkable' ppGpp variants, each possessing a diazirine cross-linker and a biotin residue as an affinity handle (Fig. 2a) . When added to cell lysates, these molecules should bind ppGpp effectors and, after UV activation, covalently biotinylate them, thus enabling affinity enrichment and subsequent identification through mass spectrometry (Fig. 2b) .
We synthesized cross-linkable ppGpp molecules by conjugating ppGpp to peptides furnishing the cross-linker and biotin. We used Fmoc chemistry to synthesize four peptide precursors, each with a bromoacetyl group and a spacer; the length of this spacer was varied to maximize the likelihood of efficient protein capture (Fig. 2a) . The peptides were conjugated to ppGpp analogs bearing a thiophosphate nucleophile, ppGpp(5′ β S) and ppGpp(3′ β S), which were synthesized with the GDP pyrophosphokinase YjbM 17 and thiophosphate analogs of ATP and GDP ( Supplementary  Fig. 2a,b) . In total, we generated eight cross-linkable ppGpp variants at milligram scales ( Supplementary Fig. 2c,d ) that were combined and used as a cocktail. Although the peptide moiety attached to the ppGpp analogs could in principle interfere with binding to target proteins, we noted that in known ppGpp-effector complex structures, at least one β -phosphate of ppGpp remains solvent exposed (Supplementary Table 2 ).
Mass spectrometry identification of ppGpp effectors.
To identify ppGpp effectors, we used E. coli strain AT713, a lysine and arginine auxotroph that facilitates stable-isotope labeling with amino acids in culture (SILAC) mass spectrometry experiments 18 . We generated two lysates, one from cells grown with heavy-isotope-labeled lysine/ arginine and the other from cells grown with regular lysine/arginine (Fig. 2b ). We added cross-linkable ppGpp to both lysates but added an excess of unmodified ppGpp only to the unlabeled lysate. After UV exposure to drive cross-linking, the two reactions were combined, and biotinylated proteins were enriched by streptavidin pulldown and subsequent trypsin digestion and mass spectrometry to identify tryptic fragments with an enrichment of heavy isotopes ( Fig. 2b and Supplementary Fig. 2e ).
We performed this capture-identification approach on three independent biological replicates. In total, the mass spectrometry identified 290 cytoplasmic proteins with at least two unique peptides in at least two replicates (Supplementary Dataset). Importantly, peptide fragments from 20 of 28 proteins shown previously to bind or be inhibited by ppGpp in vitro had high (> 2.8, or 1.5 on a log 2 scale) heavy-to-light ratios ( Fig. 2c and Supplementary Table 1 ). These observations indicated that our SILAC-based mass spectrometry approach has high sensitivity for identifying ppGpp-binding proteins. Of the eight proteins not identified, seven had no peptide fragments detected in our mass spectrometry (five of these seven are not highly expressed during exponential-phase growth 19 ), and one, RpoC, was detected but had a heavy-to-light ratio < 2.8, possibly because its binding site may not have been able to accommodate our cross-linkable ppGpp 11 . To generate a list of possible ppGpp effectors, we selected the proteins with average heavy-to-light ratios greater than 2.8, yielding 56 hits, or ~20% of the 290 proteins identified (Table 1 and Fig. 2c ). This set included 17 proteins involved in translation and 32 metabolic enzymes. The translation-related proteins included 15 GTPases that participate in various aspects of ribosome biogenesis and the translation process itself 20 . These proteins each bind tightly to GTP and/or GDP and, perhaps not surprisingly, also bind the structurally similar nucleotide ppGpp, although not all GTPases were identified in our screen. The metabolic enzymes identified participate in multiple pathways, many of whose functions are essential to growth in our culturing conditions ( Cross-linkable ppGpp (far left) was then added to cell lysates either alone or with an excess of ppGpp, and samples were exposed to UV to trigger cross-linking. Captured proteins were enriched on the basis of streptavidin affinity and, after trypsin digestion, were sequenced by MS2. Proteins that interact specifically with ppGpp should yield tryptic fragments with high heavy/light ratios. c, Plot of mean heavy/light ratios from three independent experiments for each protein identified (additional data in Supplementary Dataset). Dotted line indicates the threshold used to select hits listed in Table 1 Table 3) . For each reaction, we included key substrates and allosteric effectors at levels approximating their steady-state concentrations in exponential-phase, glucose-fed E. coli 21 (Methods). We found that ppGpp at 1 mM activated GpmA by ~50%; inhibited SpeC, Gpt, Hpt, Gsk, and PurF by more than 75% each; and had modest (< 20%) effects on seven others.
ppGpp drives a decrease in purine-nucleotide synthesis. One of the enzymes inhibited only partially by ppGpp was a uracil phosphoribosyltransferase (Upp) (PRTase; Supplementary Fig. 3a ). This modest effect may reflect the moderate K d of Upp for ppGpp (47 μ M) and the fact that ppGpp competes for binding to Upp with GTP, which was initially included at 1 mM ( Supplementary Fig. 3b ). Although GTP levels are in the low-millimolar range during exponential growth 21 , they may decrease during the stringent response in E. coli 22 . Strikingly, we found that when GTP levels were decreased to 100 μ M, ppGpp became a much more potent inhibitor of Upp (Supplementary Fig. 3b ). Thus, a decrease in GTP during the stringent response may potentiate the ability of ppGpp to inhibit Upp and other enzymes that rely on GTP.
To directly test whether ppGpp triggers a change in the levels of GTP, we extracted and profiled soluble metabolites from E. coli cells through hydrophilic chromatography in tandem with mass spectrometry (pHILIC-MS). We profiled the WT-control and RNAP 1 -2 -strains, each expressing RelA′ , or RelA′ D275G as a control. Strikingly, we found that the levels of all guanosine 5′ nucleotides (GTP, GDP, and GMP) decreased significantly after RelA′ induction in both the WT-control and RNAP 1 -2 -strains (Fig. 3a) , whereas ppGpp accumulated in both strains, as expected (Fig. 3b) . The strains in this experiment were grown in M9GAV, a medium in which cells must synthesize purine nucleotides de novo. Thus, our results strongly indicate that ppGpp blocks the de novo synthesis of guanosine 5′ nucleotides and does so independently of its effects on transcription through binding to RNAP.
We did not observe a significant decrease in ATP or other adenosine 5′ nucleotides after inducing ppGpp (Fig. 3a) . However, we hypothesized that ppGpp might block the synthesis of adenosine nucleotides and also decrease its consumption, thus leading to a minimal net change in the abundance of adenosine 5′ nucleotides. To directly test this possibility, we pulse-treated MG1655 cells in M9GAV medium with [ 13 C 2 , 15 N]glycine either before or 5 min after induction of ppGpp, a building block for purine synthesis ( Supplementary Fig. 3b ). Metabolites were then extracted from cells over time, and the incorporation of heavy isotopes into purine nucleotides was monitored by LC-MS. The rate of both ATP and GTP synthesis decreased by ~65% after ppGpp induction, on the basis of the initial velocity of heavy-glycine incorporation into adenosine and guanosine 5′ nucleotides, respectively (Fig. 3c) . These results demonstrated that ppGpp inhibits the de novo synthesis of all purine nucleotides. ppGpp inhibits de novo purine synthesis by targeting PurF. How does ppGpp block de novo synthesis of purine nucleotides? E. coli, like most organisms, assembles nonpurine building blocks into inosine monophosphate (IMP), which then feeds into the synthesis of adenosine and guanosine nucleotides (Fig. 3d) . No enzymes specific to IMP biosynthesis have previously been implicated as ppGpp targets, but our screen identified PurF, which catalyzes the first step of the pathway 23 (Table 1 and Fig. 3d ). PurF is a glutamine amido-PRTase that consists of an N-terminal glutaminase (Glnase) domain, a middle PRTase domain, and a helical sequence at the C terminus. The enzyme forms a homotetramer in solution 23, 24 . During catalysis, ammonia generated at the Glnase center is channeled to the PRTase center, where it substitutes the diphosphate group in pRpp, thus giving rise to 5′ -phosphoribosylamine 24 ( Fig. 4a) . Using ITC, we found that ppGpp binds two sites in the PurF tetramer, with identical K d of 1.6 μ M (Fig. 4b) . Titrating in ppGpp also led to a strong inhibition of PurF activity in vitro, and the inhibition was competitive with respect to the substrate pRpp ( Supplementary Fig. 4a ).
To assess whether ppGpp targets PurF in vivo, we examined the metabolite profiles of E. coli before or after ppGpp induction via pRelA′ . IMP biosynthesis requires ten sequential steps, the first eight of which take input only from PurF activity 25 ( Supplementary  Fig. 3b ). Strikingly, for WT-control cells grown in M9GAV, we observed a dramatic (> 30-fold) decrease in all three detectable intermediates downstream of PurF, as well as IMP, after the induction of ppGpp (Fig. 4c) . These results strongly support the conclusion that ppGpp targets PurF in vivo. GMP and AMP, two other known PurF inhibitors 23 , could not account for the observed inhibition of PurF, because their abundance also decreased after RelA′ expression (Fig. 3a) . Similar but less pronounced decreases in IMPsynthesis intermediates were seen for the RNAP 1 -2 -strain, suggesting that ppGpp may affect purine synthesis both transcriptionally and post-transcriptionally (Fig. 4c) .
ppGpp binding disrupts the PRTase active site of PurF. To better understand how ppGpp directly inhibits PurF, we solved a crystal structure of E. coli PurF bound to ppGpp to a resolution of 1.95 Å (Supplementary Table 4 ). The asymmetric unit of the crystal was a PurF tetramer with D2 symmetry (Fig. 4d) . The ppGppbinding sites are located where Glnase domains interact across a two-fold symmetry axis. Pairs of binding sites overlap across this two-fold axis, thereby precluding the binding of ppGpp to one site if the neighboring site is occupied, a finding that explains why the symmetric tetramer binds only two ppGpp molecules (Fig. 4d,e) . The electron density for all sites was equivalent, indicating that ppGpp binds in both possible orientations with one-half occupancy ( Fig. 4e and Supplementary Fig. 4b ). The nucleotide adopts a compact conformation in which all four phosphate groups coordinate a Mg 2+ cation with a slightly distorted square-planar octahedral configuration (Supplementary Fig. 4c and Methods).
Notably, PurF adopts an inactive conformation in complex with ppGpp, on the basis of comparison to a prior structure in complex with the substrate analog carboxylic pRpp (cpRpp), which is thought to represent the active state 24 ( Fig. 4f and Supplementary  Fig. 4d ). In particular, the fourth α -helix of the PRTase domain, which normally constitutes part of the active site in the cpRpp-analog-bound, active conformation, appears partially unwound in our ppGpp-bound structure (Fig. 4f) . Additionally, binding of ppGpp appears to disrupt a loop near the Glnase active site and to promote contacts between this loop and the C-terminal helix of PurF ( Supplementary Fig. 4d , left). The C-terminal helix is thus drawn away from the PRTase active site (Fig. 4f) , such that the side chain of Asp484 no longer stabilizes the dipole of α -helix-4 of the PRTase domain, as it does in the active, cpRpp-bound state ( Supplementary  Fig. 4d , right). These observations are consistent with our finding that ppGpp competitively inhibits PurF ( Supplementary Fig. 4a ) even though it binds at an allosteric site. In agreement with this competitive-inhibition model, the presence of pRpp at 0.5 mM, an order of magnitude higher than the K m of this substrate 23 , strongly diminished binding by ppGpp in ITC studies (Fig. 4b) .
The binding of ppGpp to PurF was found to involve four basic residues from one or both subunits: Arg45, Arg58, His59, and Arg62 (Fig. 5a ). The side chain of each residue appears to stabilize the anionic phosphate cluster of ppGpp through electrostatic interactions, with one Arg62 π -stacking to the guanine base. The guanine base also acts as a hydrogen-bond donor to the Ala82 backbone and the Asn48 side chain, whose orientation is stabilized by hydrogenbonding to the backbone of Ser81 (Fig. 5a ). To validate these interactions, we purified PurF variants in which Arg45, Asn48, Arg58, His59, or Arg62 was mutated to alanine, and assayed each mutant for binding to and inhibition by ppGpp. Strikingly, both R45A and R62A completely abolished binding to ppGpp, whereas R58A and H59A increased the K d by 16 and 39 fold, respectively (Fig. 5b) . Each of these four mutations rendered PurF insensitive to ppGpp up to 1 mM while retaining activity comparable to, or even slightly higher than, that of the WT PurF in the absence of ppGpp (Fig. 5b ).
PurF is inhibited by ppGpp in vivo.
To assess whether the ppGppPurF interaction seen in vitro also occurs in vivo, we introduced a sequence encoding the R45A mutation into purF at its native locus on the E. coli chromosome. Importantly, although PurF R45A is incapable of binding ppGpp, it preserved a WT level of catalytic activity and remained sensitive to the known feedback inhibitors AMP and GMP ( Fig. 5b and Supplementary Fig. 5a ). We transformed the PurF R45A mutant, and a WT strain for comparison, with the pRelA′ plasmid and then grew each strain to mid-exponential phase in M9GAV before inducing the production of ppGpp. We extracted metabolites immediately before and at several time points after inducing ppGpp for up to 15 min. Notably, ppGpp accumulated at comparable rates and plateaued 8 min after induction at a similar level in both strains ( Supplementary Fig. 5b ). We found that IMP, GMP, GDP, and GTP all decreased substantially in the WT, but not as much in the PurF R45A strain (Fig. 5c ). In fact, the summed levels of all guanosine nucleotides, including (p)ppGpp, and of all adenosine nucleotides increased significantly in the PurF R45A mutant but not the WT ( Fig. 5d and Supplementary Fig. 5b ).
These results support the conclusion that PurF R45A is not properly inhibited by ppGpp, leading to greater production of purine nucleotides than in the WT strain. However, our metabolite profiling indicated that intermediate species downstream of PurF, namely GAR, FGAR, and AICAR, still decreased in the PurF R45A mutant (Fig. 5e ). These lower levels are likely to reflect the inhibition of pRpp synthase by ADP 26 , which accumulates in both strains after ppGpp induction, probably from the AMP generated concomitantly with ppGpp production ( Fig. 5e and Supplementary Fig. 5b-d ). In the WT, ADP levels initially increased and pRpp levels decreased, then recovered to preinduction levels. In contrast, the PurF R45A mutant showed higher and sustained accumulation of ADP and a concomitant, continued decrease in pRpp over the 15-min time course. Notably, the accumulation of two inhibitors of the PurF R45A, AMP and GMP ( Fig. 5c and Supplementary Fig. 5b-d) , in the mutant strain did not lead to the recovery of pRpp levels to those observed in the WT, indicating that a limitation of pRpp production is the primary cause of the depletion of IMP-biosynthesis intermediates in the PurF R45A strain. Supplementary Fig. 4b . f, Comparison of the inactive conformation of PurF bound to ppGpp (left) to the active conformation of PurF bound to carboxylic pRpp (cpRpp, right), with an overlay of the two in the middle. α -helical elements involved in key rearrangements are highlighted. The PurF-ppGpp structure is colored on the basis of domains as in e, with ppGpp in yellow sticks, and the PurF-cpRpp structure is in light gray with cpRpp in cyan sticks.
In summary, our metabolite profiling indicated that E. coli bearing a ppGpp-insensitive PurF R45A accumulates purine nucleotides after ppGpp induction, probably because of continued synthesis by the PurF R45A mutant and a decrease in consumption, owing to rRNA-synthesis inhibition. Together, our results strongly support the conclusion that PurF is normally inhibited by ppGpp in vivo and that relieving this inhibition leads to a dysregulation of purinenucleotide synthesis.
Discussion
ppGpp plays a central role in regulating the growth rate of virtually all prokaryotes. Despite its importance and intensive study over several decades, a comprehensive list of ppGpp targets has been elusive. Development of a capture compound for systematically identifying its effectors by mass spectrometry provides an unprecedented global view of how ppGpp regulates cellular activities in E. coli. Our approach identified 56 candidate ppGpp-binding proteins, including almost all of those previously identified and more than 25 not previously implicated as targets (Table 1) .
Notably, some of the identified proteins bound to ppGpp with a K d in the mid-to high-micromolar range, but 1 mM ppGpp did not markedly affect their biochemical activities in vitro. For these proteins, enzymatic inhibition by ppGpp may require the inclusion of substrates, cofactors, or other proteins present in cell lysates but not included in vitro. Some of these proteins may also represent false positives or may have been identified because they interact with a bona fide ppGpp effector and were cross-linked as a result of their proximity. Detailed studies, as performed here for PurF, are needed to validate the candidates identified and assess their in vivo relevance.
ppGpp has long been known to inhibit DNA replication, transcription, translation, and various anabolic processes 4 , but the set of direct effectors had been elusive. In E. coli, ppGpp directly binds RNAP, and RNAP is often considered the primary target of ppGpp. However, cells producing a variant of RNAP that no longer binds ppGpp were still growth inhibited by ppGpp (Fig. 1d) , indicating transcription-independent mechanisms for inhibiting cell growth. Our capture-compound-based method identified dozens of putative targets that control a wide range of cellular and metabolic processes, suggesting that ppGpp orchestrates the shutdown of many physiological processes in parallel.
One highly enriched set of putative targets were GTPases, 15 of which are conserved proteins involved in translation and ribosome biogenesis 20 ( Table 1 ). For EF-G, EF-Tu, and IF2, the binding of ppGpp instead of GTP disrupts translation in vitro 27, 28 . How ppGpp affects the other GTPases is not known, but it probably leads to a similar disruption in translation. Testing the physiological relevance of individual GTPases as targets will be difficult, because mutations that eliminate binding of ppGpp to one or even several GTPases may have little effect on translation. This difficulty may highlight a key feature of ppGpp-based control; targeting multiple GTPases is a potentially fail-safe mechanism for inhibiting translation.
Another highly enriched set of ppGpp targets are enzymes involved in nucleotide metabolism. (p)ppGpp has previously been shown to block GTP synthesis in the distantly related Grampositive Bacillus subtilis by inhibiting the guanylate kinase Gmk 29, 30 . Blocking GTP synthesis was suggested to be important for inhibiting rRNA transcription, which relies on GTP as the initiating nucleotide 31 , because (p)ppGpp does not target B. subtilis RNAP. However, we found that GTP synthesis is also blocked in E. coli, suggesting that blocking GTP synthesis has broader relevance during the stringent response. Lowering GTP levels may significantly slow growth, because GTP is needed for transcription and translation. The decrease in GTP also potentiates ppGpp as a competitor for some GTP-activated enzymes, as shown here for Upp, and a decrease in GTP synthesis may prevent the excessive accumulation of ppGpp, thereby enabling an eventual resetting of the stringent response and resumption of cell growth.
How does ppGpp inhibit purine-nucleotide biosynthesis? Prior studies have found that ppGpp inhibits the salvaging of guanine and hypoxanthine nucleobases or nucleosides by targeting Hpt and Gpt
32
, two proteins also identified here (Fig. 3d and Table 1 ). In addition, our results demonstrate that ppGpp blocks de novo purine synthesis by directly targeting PurF, which catalyzes the first dedicated step of the pathway. We found that ppGpp strongly inhibited PurF in vitro ( Supplementary Fig. 4a) , and the induction of ppGpp in vivo significantly decreased the metabolites downstream of PurF (Fig. 4c) as well as the rates of purine-nucleotide synthesis (Fig. 3c) . Notably, in cells producing PurF R45A, which retains WT PurF activity and regulation except by ppGpp, we found that purine-nucleotide levels were significantly higher than those in the WT after ppGpp induction (Fig. 5d) , underscoring the physiological relevance of PurF as a direct target.
In summary, our work indicates that inhibiting nucleotide synthesis is a critical facet of growth control by ppGpp in E. coli, and probably other bacteria, and PurF is a key direct target. More broadly, our capture-compound approach indicates that ppGpp regulates cell growth by targeting a range of cellular and metabolic processes, and the specific targets identified can now be examined in detail. Our capture compounds could also be used to rapidly identify the stringent-response effectors in a range of microbes, including pathogens, many of which rely on ppGpp to survive in their hosts 10 . A comparison of effectors in phylogenetically diverse organisms will also begin to reveal how the stringent response has evolved.
online content
Any methods, additional references, Nature Research reporting summaries, source data, statements of data availability and associated accession codes are available at https://doi.org/10.1038/ s41589-018-0183-4. Cells were cultured at 37 °C and 200 r.p.m. on an orbital shaker (for liquid cultures). Before liquid-culture growth, individual colonies were selected by growth overnight on LB agar plates. Antibiotics were used at the following concentrations unless otherwise noted: carbenicillin, 100 µ g/mL; kanamycin, 50 μ g/mL; chloramphenicol, 25 µ g/mL; and tetracycline, 12.5 μ g/mL.
Methods

Growth conditions. Escherichia coli
Plasmid construction. All DNA-oligonucleotide primer sequences used in this study can be found in Supplementary Table 5 .
The IPTG-inducible RelA′ expression plasmid (pR1-1His) was modified from pALS13 (ref. 15 ), a gift from S. Lovett (Brandeis University). To insert an octahistidine tag at the C terminus of the RelA′ open reading frame, we PCRamplified the plasmid with primers 'R1-1 His8ins RP' and 'R1-1 His8ins RP' and treated the PCR reaction with DpnI before transformation into E. coli DH5α . pR1-1His plasmids were extracted from a transformant.
Plasmids for recombinant-protein production were constructed from a vector backbone (Supplementary Table 6 ) and a PCR fragment of the target-proteincoding sequence (insert DNA, Supplementary Table 7) through Gibson assembly. Plasmids pET30-His 6 -SUMO-CfaN and pTXB1-Ub-Cfa were generous gifts from T. Muir (Princeton) 33 . Single-point mutagenesis was performed on expression plasmids for PurF (pG23-1Cfa) and RelA′ . Briefly, the original plasmid was PCR-amplified with primer pairs bearing the desired mutation, and each PCR reaction was treated with DpnI before transformation into E. coli DH5α . Mutant plasmids were extracted from transformants. A summary of plasmids used in this study can be found in Supplementary Table 8 .
Construction of the PurF R45A strain. The PurF R45A strain (ML2912) was also constructed in an MG1655 (ML006) background through lambda recombineering 34 . ML006 bearing pKD46 and expressing the lambda recombinase was electroporated with a kan R fragment amplified from pKD4 with primers 'G23-1 K46:Kan FP' and 'G23-1 K46:Kan RP' . Recombinants were selected on LB plates containing 10 μ g/mL kanamycin and 100 μ g/mL carbenicillin at 30 °C to maintain pKD46. Then a recombinant clone expressing the lambda recombinase was electroporated with the primer 'G23-1 R45A Rec' . This second recombination displaced the kan R cassette and restored the purF gene bearing the desired mutation. Recombinants were selected for purine autotrophy on M9-glucosecasamino acid plates at 37 °C to drive the loss of pKD46. The desired mutation was confirmed by Sanger sequencing, and the absence of unexpected mutations was confirmed by whole-genome sequencing. A list of all strains used in this study can be found in Supplementary Table 9 .
Protein expression. All recombinant proteins used in this study were expressed in E. coli BL21(DE3) bearing the corresponding expression plasmid. Expression strains were grown in LB containing the appropriate antibiotics at 37 °C to OD 600 = 0.6. The culture was then cooled to 18 °C and then induced by the addition of 200 μ M IPTG. Cells were harvested 16-24 h after induction.
Purification of proteins without an affinity tag. The expression plasmids for PurA from E. coli (G27-1nt) and PurF from E. coli (G23-1nt) encoded the exact open reading frame of each protein. These proteins were purified through similar strategies, as exemplified by E. coli PurA, as follows. Cell pellets from 1 L expression culture (wet weight ~10 g) was resuspended in 40 mL lysis buffer containing 50 mM Tris-HCl, pH 8.0, 50 mM NaCl, 10 mM MgCl 2 , 5 mM DTT, 20 μ g/mL lysozyme, and 1 mM PMSF. Cells were disrupted through sonication, and the lysate was cleared at 15,000g for 10 min. The supernatant was then treated with 75 mg protamine sulfate and vortexed. Precipitate that emerged was pelleted at 30,000g for 1 h, and the cleared lysate was applied to a DEAE Sepharose column (16/150, ~30-mL bed volume) equilibrated with buffer A (50 mM Tris-HCl, pH 8.0, 10 mM MgCl 2 and 5 mM DTT). The column was then washed with 50 mL 5% buffer B (buffer A + 1 M NaCl), and bound protein was eluted with a linear gradient with the percentage of buffer B increasing from 5% to 55% within 200 mL. Peak fractions for PurA (15 mL) were combined, and a saturated (NH 4 ) 2 SO 4 solution at 0 °C was added to reach 55% saturation. Precipitated protein was removed, and (NH 4 ) 2 SO 4 was added to the mother liquor to 65% saturation. Protein precipitated at this stage had high purity, as examined by SDS-PAGE.
The protein was redissolved in gel-filtration buffer (20 mM HEPES-Na, pH 7.4, 150 mM NaCl, 2 mM MgCl 2 , and 1 mM TCEP) and refined over a Superdex-200 increase (10/300) column.
Purification of hexahistidine-tagged proteins. With the exception of B. subtilis
YjbM (G1-2), histidine-tagged proteins were purified with the standard protocol described below. The cell pellet from 1 L of expression culture was resuspended in 25 mL lysis buffer containing 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 2 mM MgCl 2 , 1 mM TCEP, 20 μ g/mL lysozyme, and 1 mM PMSF. Cells were disrupted through sonication, and the lysate was cleared at 30,000g for 1 h. Cleared lysate was applied to 4 mL Ni-NTA resin equilibrated with lysis buffer, and was allowed to flow through by gravity. The Ni-NTA resin was washed with five column volumes of wash buffer 1 (50 mM Tris-HCl, pH 8.0, 500 mM NaCl, 10 mM imidazole, 2 mM MgCl 2 , and 1 mM TCEP) and ten column volumes of wash buffer 2 (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 25 mM imidazole, 2 mM MgCl 2 , and 1 mM TCEP). Bound protein was eluted with three column volumes of elution buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 300 mM imidazole, 2 mM MgCl 2 , 1 mM TCEP, and 15% (vol/vol) glycerol).
For the purification of His 6 -YjbM, cells were lysed in a buffer containing 50 mM Tris-HCl, pH 8.0, 300 mM NaCl, and 1 mM DTT, and neat glycerol was mixed into the lysate for 15% (vol/vol) final concentration immediately after lysis. After adsorption of protein from the lysate, the Ni-NTA resin was washed with ten column volumes of wash buffer (50 mM Tris-HCl, pH 8.0, 300 mM NaCl, 35 mM imidazole, 1 mM TCEP, and 15% (vol/vol) glycerol), and bound protein was eluted with three column volumes of elution buffer (wash buffer with 500 mM imidazole). Protein in the eluate was concentrated and refined over a Superdex-200 increase (10/300) column.
Removal of affinity tags. To avoid interference from oligohistidine sequences, we removed the affinity tags from most proteins used for hit-validation experiments. Standard procedures for thrombin cleavage, SUMO-protease cleavage, and thiol cleavage for this purpose are described below.
To remove the N-terminal hexahistidine tag of recombinant proteins expressed from the pET28b vector, we reconstituted thrombin (Sigma) in 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 20% (vol/vol) glycerol at 100 U/mL. Eluates from the Ni-NTA column were dialyzed against 20 mM Tris-HCl, pH 8.0, 150 mM NaCl, and 2 mM MgCl 2 , then treated with thrombin (10 U per μ mol cleavage sites) at room temperature overnight. Cleavage was monitored by SDS-PAGE, and more thrombin and cleavage time was applied if necessary. After completion, the cleavage mixture was treated with 10 mM TCEP, concentrated, and refined over a Superdex-200 increase (10/300) column.
To remove the N-terminal His 6 -SUMO tag fused to E. coli PyrH (G25-1Sumo) and GuaB (G30-1Sumo), we exchanged proteins eluted from the Ni-NTA column into a SUMO-cleavage buffer containing 20 mM HEPES-Na, pH 7.4, 150 mM NaCl, 2 mM MgCl 2 , and 1 mM TCEP. The tagged protein was then treated with SUMO protease (1 mg per micromole cleavage sites) at room temperature for 2 h. E. coli PyrH generated in situ from G25-1SUMO was used directly for biochemical assays. The cleavage mixture of E. coli GuaB (G30-1SUMO) was subjected to a reverse Ni-NTA process to clean up residual uncleaved protein. The combined flow through and wash were then concentrated and refined over a Superose-6 increase (10/300) column.
Proteins fused to a C-terminal Cfa-His 6 were exchanged into intein-cleavage buffer containing 20 mM HEPES-Na, pH 7.0, 150 mM NaCl, and 1 mM TCEP, and treated with 100 mM sodium 2-mercaptoethanesulfonate, 100 mM l-cysteine, and 20 mM TECP at pH 7.0 and room temperature overnight. This treatment substituted a cysteine residue for the Cfa-His 6 tag, harnessing the autocatalytic N-terminal cleavage activity of inteins 8 . Cleavage was monitored by SDS-PAGE and, if necessary, was allowed to progress further at 37 °C. After completion, the cleavage mixture was extensively dialyzed against intein-cleavage buffer and then subjected to a reverse Ni-NTA process to remove residual uncleaved protein.
The combined flow through and wash were concentrated and refined over a Superdex-200 increase (10/300) column.
Size-exclusion chromatography (SEC).
With the exception of B. subtilis YjbM and E. coli GuaB, SEC of all recombinant proteins was run in a buffer containing 20 mM HEPES-Na, pH 7.0, 150 mM NaCl, 2 mM MgCl 2 , and 1 mM TCEP. Up to 20 mg protein was injected in 1 mL, and peak fractions were collected. SEC buffer for E. coli GuaB included 150 mM KCl in place of NaCl. SEC buffer for YjbM contained 20 mM Tris-HCl, pH 8.0, 300 mM NaCl, 1 mM TCEP, and 15% (vol/vol) glycerol.
Synthesis of native and cross-linkable ppGpp. ppGpp was synthesized with procedures described by Steinchen et al. 17 . Briefly, 10 mM GDP and 12 mM ATP were mixed with 5 μ M YjbM (final concentrations, molarity in monomers for YjbM). The mixture was incubated at 37 °C for 4 h. ppGpp was then purified through MonoQ anion-exchange chromatography, then precipitated with LiCl and ethanol. The precipitate was lyophilized, thus yielding a colorless powder. ppGpp(3′ β S) was synthesized from ATP-γ S and 1.2 equivalents of GDP, and ppGpp(5′ β S) from GDPßS and 1.2 equivalents of ATP through otherwise identical procedures.
All bromoacetylated peptides were synthesized with standard Fmoc chemistry 35 (details in Supplementary Note). Coupling-deprotection cycles were performed with Fmoc-Gly-OH, Fmoc-Lys(Alloc)-OH, and Fmoc-Gly-OH (in that order), and the N-terminal amine was biotinylated. Thereafter, The Alloc group protecting the lysine side chain was removed by treatment with Pd(PPh 3 ) 4 , and the branch was synthesized through coupling-deprotection cycles with Fmoc-photoMet-OH followed by a spacer amino acid. The N terminus of the branch was then bromoacetylated with 40 μ L bromoacetic anhydride with the presence of DIEA, and the peptide was cleaved from the resin and purified through semipreparative reverse-phase HPLC.
Cross-linkable ppGpp was synthesized by conjugation of each bromoaceylated peptide (3a-d) to equimolar ppGpp(3′ β S) (for 1a-d) or to ppGpp(5′ β S) at pH 6.2 (for 2a-d) at 42 °C for 2 h. Each conjugate was purified from a 2-μ mol-scale reaction with a MonoQ (5/50) column at 4 °C, through a linear gradient of buffer A (5 mM HEPES-Na, pH 7.0) and buffer B (5 mM HEPES-Na, pH 7.0, and 1 M NaCl). Cross-linkable ppGpp was stable at -80 °C for at least three months. For MS analysis, each conjugate was first adsorbed to C18-Ziptips (Millipore) for desalting and subsequent elution in 50% (vol/vol) acetonitrile containing 1 mM ammonium formate. The eluate was then analyzed with a Bruker Daltonics APEXIV 4. N 4 ]arginine (the heavy medium). Lysates were prepared in 20 mM HEPES-Na, pH 7.0, 100 mM NaCl, 0.2 mM PMSF, and 10 μ g/mL lysozyme at 4.5 mg / mL protein. Compounds 1a-d and 2a-d were mixed in equimolar amounts in a 0.5 mM cocktail. Two reactions were then assembled in adjacent wells on a 96-well plate chilled on ice. The effector-capture reaction consisted of 540 μ g protein from the heavy lysate, 100 μ M cross-linkable ppGpp cocktail, 10 mM MgCl 2 , and 1 mM MnCl 2 . The control reaction consisted of 540 μ g protein from the light lysate, 100 μ M cross-linkable ppGpp cocktail, 5 mM native ppGpp, 15 mM MgCl 2 , and 1.5 mM MnCl 2 . After exposure to a 365-nm UV lamp for 2 min, reactions were then combined and extensively exchanged in a concentrator (10-kDa molecular-weight cutoff) into a buffer containing 20 mM HEPES-Na and 200 mM NaCl. At that stage, 50 μ g protein was saved for input control, and the rest was concentrated to 100 μ L, diluted with 400 μ L RIPA buffer (50 mM Tris, pH 7.5, 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, and 1% Triton X-100) and incubated overnight with 200 μ L MyOne Streptavidin C1 Dynabeads (Thermo Fisher Scientific) at 4 °C. On the second day, the protein in supernatant (flow through) was sampled for western blotting and then removed, and the Dynabeads were washed at 4 °C twice with RIPA buffer, once with 0.1 M Na 2 CO 3 , twice with 100 mM Tris, pH 8.0, 5 M guanidinium chloride, and twice more with RIPA buffer. Bound protein was eluted by boiling the Dynabeads in 40 μ L SDS-PAGE loading dye containing 2 mM biotin.
Tryptic-fragment preparation. For input controls, the lysate mixture (50 μ g protein) was treated with 10 mM DTT at 56 °C for 1 h followed by 55 mM iodoacetamide at room temperature for 1 h in the dark, then digested with 1 μ g trypsin (Promega) at room temperature overnight. Thereafter, the sample was acidified with formic acid (5% final concentration) and applied to C18 SpinTips (Protea Biosciences). After being washed with 0.1% formic acid in water, tryptic fragments were eluted with 80% acetonitrile in water containing 0.1% formic acid. The eluate was dried in a SpeedVac and reconstituted in 100 μ L and then diluted 1:50 in 0.1% formic acid; 5 μ L of the diluted eluate was used for LC-MS2 analysis.
Eluates from streptavidin Dynabeads were first resolved on a 12% SDS-PAGE gel, which was subsequently stained with Coomassie brilliant blue, which revealed three major protein bands: the streptavidin at 13 kDa, EF-Tu at 40 kDa, and EF-G at 80 kDa. The gel lane for each eluate was excised, and regions below the 15-kDa or above the 200-kDa markers were trimmed. The lane was further divided into three samples and processed separately: the EF-Tu and EF-G bands (sample A), the fragment below EF-Tu (sample B), and the rest (sample C). The gel fragments were diced into 1-mm pieces, then treated with 10 mM DTT at 56 °C for 1 h followed by 55 mM iodoacetamide at room temperature for 1 h in the dark. After a brief wash with 0.1 M NH 4 HCO 3 , gel pieces were dehydrated with acetonitrile, dried in a SpeedVac, and rehydrated with a minimal volume of 6 ng/μ L trypsin in 0.1 M NH 4 HCO 3 for digestion at room temperature overnight. Thereafter, tryptic fragments were extracted by four shrinking-swelling iterations. In each iteration, gel pieces were first dehydrated with 5% formic acid in 50% (vol/vol) acetonitrile (first two iterations) or neat acetonitrile (second two). Supernatant containing tryptic fragments was then removed for collection, and gel pieces were reswelled with 0.1 M NH 4 HCO 3 in water. The combined supernatant was dried in a SpeedVac and reconstituted in 50 μ L 0.1% formic acid, and 5 μ L was used for LC-MS2 analysis.
LC-MS2-based proteomics. Tryptic fragments were separated by reverse-phase HPLC (Thermo Easy nLC1000) with a precolumn (made in house, 6 cm of 10-µ m C18) and a self-packing 5-µ m-tip analytical column (12 cm of 5 µ m C18, New Objective) over a 140-min gradient before nanoelectrospray with a QExactive mass spectrometer (Thermo). Raw mass spectral data files (.raw) were searched with 
(R)
. Only peptides with a Mascot score greater than or equal to 25 and an isolation interference less than or equal to 30 were included in the data analysis.
Effector capture and LC-MS2 identification were performed on three biological replicates. SILAC quantification was obtained by using the area of the precursor-ion peaks. In the case of missing detection of the light or heavy ion, a SILAC ratio of 10 or 0.1 was arbitrarily assigned. The values were then normalized to the median relative protein-quantification ratios obtained from the corresponding loading controls. The SILAC ratio of a unique peptide sequence was calculated as the mean of all precursor ions that matched the sequence regardless of modifications. The SILAC ratio of a protein was calculated as the mean of all unique peptides mapped to the protein. Only proteins detected in at least two replicates each by at least two unique tryptic fragments were reported. SILAC ratios were converted to log 2 units, and, for each protein, the mean and P value for that log 2 (SILAC ratio) < 1 was calculated.
Metabolic profiling of E. coli. Overnight starter cultures in M9GAV were diluted to OD 600 = 0.005 in fresh medium, grown at 37 °C to an OD 600 between 0.2 and 0.3, and then treated with inducers or labeling reagents. Untreated control samples were harvested from the same culture 1 min before the treatment. RNAP 1 -2 -mutant strains ML2916 (+ pR1-1His) and ML2917 (+ pR1-1His D275G) were treated with 50 μ M or 150 μ M IPTG for growth tests and ppGpp quantification (Fig. 1c,d) ; samples for metabolite profiling were collected 15 min after treatment with 150 μ M IPTG (Figs. 3a,b and 4c) . WT-control strains ML2914 (+ pR1-1His) and ML2915 (+ pR1-1His D275G) were treated with 50 μ M or 150 μ M IPTG for growth tests and ppGpp quantification (Fig. 1c,d) ; samples for metabolite profiling were collected 10 min after treatment with 75 μ M IPTG (Figs. 3a,b and 4c ). MG1655 strain ML2920 and PurF R45A strain ML2924, both bearing pR1-1His, were induced by 40 μ M IPTG for hydrophilic metabolite profiling (Fig. 5c-e and Supplementary Fig. 5b,c) . ML2920, either uninduced or 5 min after induction with 40 μ M IPTG for hydrophilic metabolite profiling, was also treated with 0.63% [ 13 C 2 , 15 N']glycine (Fig. 3c) . Experimental procedures for metabolite extraction were modified from those described by Park et al. (p)ppGpp was quantified over a MonoQ 5/50 column: lysate equivalent to 1.0 OD 600 cells was transferred to 3.0 mL aqueous solution of 10 mM Tris-HCl, pH 8.0, and applied to the column after being passed through a 0.22-μ m syringe filter. (p) ppGpp was eluted at 4 °C with a linear NaCl gradient at pH 8.0, and the peak areas were interpolated to a working curve of external ppGpp standards.
Metabolites other than (p)ppGpp were quantified with pHILIC-MS as follows: lysates cleared from debris were lyophilized and reconstituted in 200 µ L water, and 2 μ L was injected into a ZIC-pHILIC 150 × 2.1-mm (5 µ m particle size) column (EMD Millipore) running at 0.15 mL/min. Metabolites were eluted with a linear gradient between solvent A (20 mM (NH 4 ) 2 CO 3 and 0.1% ammonium hydroxide) and solvent B (acetonitrile), with the percentage of solvent B decreasing from 80-20% over 20 min. For relative quantifications, a peak area of 1.0 × 10 4 was arbitrarily assigned to undetected metabolites. The peak area was then normalized to the ISTD amino acid with the closest retention time and ionized by the same charge for fold-change calculation. For absolute quantification of AMP, ADP, ATP, GMP, GDP, and GTP, external standards containing these nucleotides in a series of concentrations were prepared in the presence of 0.25% ISTD (vol/vol). This ISTD concentration was identical to that in reconstituted samples. Absolute quantification was achieved by interpolation of ISTD-normalized peak areas to a working curve of external standards.
PurF expression, purification, and biochemical reconstitution. PurF used for crystallization was expressed without affinity tag from the plasmid G23-1nt (Supplementary Table 5 ). PurF variants used for biochemical and ITC analyses were expressed with an autocleaving Cfa-His 6 tag from the G23-1Cfa plasmid and related mutants 33 . Expression was carried out in BL21(DE3) hosts in LB and induced at 18 °C for 20 h with 200 μ M IPTG. Lysate containing tagless PurF was first treated with protamine sulfate (8 mg per gram cell pellet) to precipitate nucleic acids, and the cleared lysate was then fractionated over a DEAE-Sepharose column. Peak fractions were combined and then subjected to fractionation with (NH 4 ) 2 SO 4 . Precipitates collected between 40% and 47.5% saturation (4 °C) were dissolved in SEC buffer (20 mM HEPES-Na, pH 7.4, 150 mM NaCl, 2 mM MgCl 2 , and 1 mM TCEP). PurF-Cfa-His 6 was purified over a Ni-NTA column with standard protocols, and the eluate was treated with 100 mM sodium 2-mercaptoethanesulfonate, 100 mM l-cysteine, and 20 mM TECP, pH 7.0, at room temperature overnight. This treatment substituted a cysteine residue for the Cfa-His 6 tag 37 . The cleavage mixture was extensively dialyzed against SEC buffer and then subjected to a reverse Ni-NTA process. All PurF proteins were refined over a Superdex-200 column running in SEC buffer before analytical applications.
Biochemical analysis was performed in 100-μ L reactions in a 96-well plate at 25 °C. Each reaction contained 50 mM HEPES-Na, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM TCEP, 5 mM glutamine, 5 mM ATP, 5 mM glycine, 50 nM PurF, 1 μ M E. coli PurD, 3.75 mM PEP, 0.5 mM NADH, pyruvate kinase, and lactate dehydrogenase (10 units/mL each), and the indicated amounts of pRpp-Mg and ppGpp-Mg. The absorbance of each reaction was monitored for the absorbance at 340 nm (A 340 ) every 15 s.
X-ray crystallography of the PurF-ppGpp complex. Crystals were grown by hanging-drop vapor diffusion with drops containing 2 μ L of protein (25 mg/mL PurF in 20 mM HEPES-Na, pH 7.4, 150 mM NaCl, 1 mM TCEP, 5 mM ppGpp, and 15 mM MgCl 2 ) mixed with 2 μ L of well solution (0.1 M HEPES-Na, pH 7.4, 24% PEG 3350 and 4% iPrOH) at 18 °C. After 5 d, crystals were looped out of the drop and frozen in liquid nitrogen without any cryoprotectant added. Diffraction data were collected at the APS, with the NE-CAT beamline 24-IDC on a Pilatus 6M detector.
Diffraction data were indexed, integrated, and scaled with HKL2000 (ref.
38
). The phase problem was solved by molecular replacement with PHASER 39 with chain A of PDB 1ECJ as a search model 40 . The resulting solution was isomorphous with PDB 1ECJ, with a D2 symmetric tetramer in the asymmetric unit. The model was refined with PHENIX 41 with manual model building in COOT 42 . The Ramachandran statistics were 96.36% favored, 3.64% allowed, and 0% outlier.
Modeling of ppGpp in the binding sites was complicated by the overlap between adjacent sites across a two-fold noncrystallographic symmetry (NCS) axis. Readily interpretable density for the guanosine base was observed at a low contour level in the nonoverlapping part of each site, but the density for the phosphates was in a large mass of density spanning the NCS axis, in which individual atom positions could not be readily visualized because the density was clearly the average of two overlapped NCS-related copies of ppGpp. Because the compactness of the density in the overlap region indicated that the phosphate groups must be coordinated by a divalent cation, 0.5 occupancy model structures with Mg 2+ coordinated were placed in both possible orientations and refined with tight constraints on the Mg +2 coordination. The best result was achieved with a conformation in which the four phosphates interacted with the ion with nearly ideal square-planar octahedral geometry. As expected, the refined occupancy of the NCS-related copies did not deviate significantly from the starting value.
Isothermal titration calorimetry. ITC was performed with a VP-ITC MicroCalorimeter (Malvern Panalytical). ppGpp-Mg in SEC buffer was injected at 10 nmol/injection into hit protein loaded in the sample cell. All proteins titrated were SEC purified. ppGpp and MgCl 2 were originally prepared as 100 mM and 1 M stock solutions in water, respectively. The ppGpp-Mg solution was assembled immediately before use by dilution of ppGpp and MgCl 2 in the SEC buffer at 2 mM for the titration of Upp and PurA, or 1 mM for the titration of all other proteins. Protein concentrations (counted as monomer) in the sample cell were 240 μ M for GdhA; 200 μ M for Gpt, Hpt, Upp, and PurA; 100 μ M for SpeC, Gsk, PurF, GmpA, and Mpl; and 50 μ M for Gnd, His 6 -FolC, His 6 -Cmk, His 6 -Idh, and His 6 -Pgk. For the titration of PurA, 1 mM IMP was also added to both ligand and protein solutions. Blank titrations were performed with protein-free SEC buffer in the sample cell.
ITC data were processed in Origin software (MicroCal), which automatically integrates heat signal and calculates the molar enthalpy change (Δ H m ) and the overall ligand-to-receptor molar ratio ([L]/[R]) at each injection. Δ H m was first corrected by subtracting the corresponding blank-titration data.
relationships were seen in titrations of SpeC, Upp, PurF, PurA, Gpt, and Hpt, where Δ H m approximated zero at the end of the titration. These datasets were fitted to a single-site model with both stoichiometry (n) and K d as variables. Sigmoidal isotherms were also seen in the titrations of Gsk and GdhA with ppGpp-Mg, and Δ H m was approximated as a nonzero value. We attributed this residual Δ H m to a second weak binding site and hence fitted the dataset to a sequential two-site model. Finally, if Δ H m attenuated hyperbolically with [L]/[R], the dataset was also fitted to a single-site model, but with stoichiometry (n) fixed at one site per subunit. Such isotherms were seen in the titrations of GmpA, Mpl, Gnd, His 6 -FolC, His 6 -Cmk, His 6 -Idh, His 6 -Pgk, and two PurF mutants (R58A and H59A).
Biochemical validation of other candidate ppGpp-binding proteins. General considerations. With one exception (ornithine decarboxylase), all biochemical assays were performed in 96-well plates at 25 °C in a Spectramax M5 plate reader (Molecular Devices). The volume of each reaction was 100 μ L unless noted otherwise. The absorbance of each reaction was monitored for the A 340 every 15 s. Water-soluble small-molecule reagents were dissolved in water, and the pH was adjusted to 7.4. Nucleobases (guanine, hypoxanthine, and uracil) were reconstituted in 0.1 M NaOH. All of the above chemicals were diluted to 10× working concentrations in water immediately before use. Recombinant proteins were SEC purified and diluted in SEC buffer to 10× working concentration.
Typically, a reaction was assembled by first mixing all components except one essential substrate. The left-out substrate was then simultaneously transferred to multiple wells at t = 0 to initiate the reaction.
Biochemical activities that directly produced or consumed NADH were monitored in real time on the basis of the A 340 of the reaction. Other activities were, if possible, coupled to the production or consumption of NADH to enable realtime monitoring. In particular, the production of ADP was quantitatively coupled to the stoichiometric consumption of NADH via the activity of excess pyruvate kinase (PK type III from rabbit muscle, Sigma) and lactate dehydrogenase (LDH; from rabbit muscle, Roche) by the following reaction:
where PEP is phosphoenolpyruvate. A 20× PK-LDH mixture was prepared in water, which contained PEP (monopotassium salt from Roche, 75 mM), NADH (disodium salt from Roche, 10 mM), PK, and LDH (200 units/mL each) 9 .
Uracil phosphoribosyltransferase assays. Upp catalyzes the production of UMP from uracil and pRpp:
UMP was then phosphorylated to UTP by the activities of the uridylate kinase PyrH and the nucleoside diphosphate kinase Ndk (both purified in this study):
PK-LDH then coupled ADP production to the consumption of NADH. The overall reaction was:
Each reaction contained 50 mM HEPES-Na, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM TCEP, 0.2 mM uracil, 1 mM pRpp, 5 mM ATP, 100 nM Upp, 1 μ M each E. coli PyrH and Ndk, 1× PK-LDH mixture, and the indicated amounts of GTP-Mg and/or ppGpp-Mg.
Guanine phosphoribosyltransferase (Gpt) assays. Gpt catalyzes the production of GMP from guanine and pRpp. GMP was then phosphorylated to GTP by the activities of the guanylate kinase Gmk and the nucleoside diphosphate kinase Ndk (both purified in this study). These kinase activities were coupled to NADH consumption by the activity of PK-LDH. The overall reaction was: Each reaction contained 50 mM HEPES-Na, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 1 mM TCEP, 2 mM l-aspartate, 1 mM IMP, 2 mM ATP, 300 nM PurA, 1 μ M E. coli Ndk, 1× PK-LDH mixture, and the indicated amounts of GTP-Mg and/ or ppGpp-Mg.
Inosine/guanosine kinase (Gsk) assays. Gsk catalyzes the phosphorylation of inosine (Ino) or guanosine (Guo) with ATP:
PK-LDH further coupled ADP production to the consumption of NADH. The overall reaction was:
Ino(Guo) PEP NADH H IMP(GMP) lactate NAD
Each reaction contained 50 mM HEPES-Na, pH 7.4, 150 mM KCl, 5 mM MgCl 2 , 1 mM TCEP, 500 nM Gsk, 1× PK-LDH mixture, and the indicated amounts of ATP-Mg, ppGpp-Mg, and Ino or Guo.
IMP dehydrogenase (GuaB) assays. GuaB catalyzes the oxidization of IMP into xanthosine monophosphate (XMP) and the concomitant production of NADH from NAD + : Each reaction (200 μ L) contained 50 mM HEPES-Na, pH 7.4, 150 mM NaCl, 2 mM MgCl 2 , 1 mM TCEP, 100 nM SpeC, and the indicated amounts of GTP-Mg or ppGpp-Mg. The reaction was started by addition of 1 mM ornithine and was allowed to proceed at 37 °C in a water bath for 3 min. The reaction was stopped by the addition of 100 μ L chloroform and vortexing. The aqueous layer was quantitatively recovered, diluted to 1 mL, and treated with 100 μ L 1 M phthalic anhydride in chloroform at 37 °C for 10 min with vigorous shaking. After phase separation, 500 μ L of the aqueous layer was applied to a MonoQ 5/50 column (GE Healthcare). Derivatives of ornithine and putrescine were eluted at 4 °C with a linear gradient of buffer A (5 mM HEPES-Na, pH 7.0) and buffer B (5 mM HEPES-Na, pH 7.0, and 1 M NaCl), with the percentage of buffer B increasing from 15% to 50% within 10.5 mL. Samples of pure ornithine and putrescine were derivatized and analyzed under the same conditions to identify their derivatives in the chromatogram.
Statistics. For metabolite quantification, one independent culture of the strain of interest was grown and harvested for each replicate. In enzyme-kinetic assays, each replicate was a reaction assembled with the same set of substrate/auxiliary enzyme preparations, but with different dilutions of the enzyme of interest. In all relevant figure panels, values of mean ± range (n = 2) or mean ± s.d. (n = 3) are reported, and the exact n value is described in each figure legend.
Two-tailed Student's t tests reported in Fig. 5c , d were performed with assumptions of a Gaussian distribution and equal variance. The number of degrees of freedom for all tests was 4, for n = 3 in each set.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
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Policy information about availability of computer code Data collection LC-MS and LC-MS2 data were collected using XCalibur (Thermo Fisher Scientific); UV-Vis absorbance data for enzymatic assays were collected using Softmax Pro 6.22 (Molecular devices). Acquisition of ITC data was performed using the MicroCal Origin software (Malvern Panalytical).
Data analysis
LC-MS data of metabolomic samples were analyzed using XCalibur QuanBrowser 2.2 (Thermo Fisher Scientific). LC-MS2 data of proteomic samples were searched using Proteome Discoverer 2.1 (Thermo) and Mascot version 2.4.1 (Matrix Science) for sequence identification. X-ray diffraction data were indexed, integrated, and scaled using HKL2000 and molecular replacement performed using PHASER. The model was refined using PHENIX with manual model building in COOT. ITC traces were integrated and fitted to indicated binding models using MicroCal Origin data analysis module for VP-ITC (Malvern Panalytical). Anion-exchange chromatograms were integrated using Unicorn 6.4 (GE Healthcare). Regression and plotting were performed using PRISM (Graphpad). Structures were visualized using PyMOL 2.2.1 (Schordinger LLC). Figures were prepared using Adobe Illustrator.
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Sample size
No sample size calculation is performed. We performed the capture-identification experiment in three biological replicates to assess the reproducibility of peptide identification. We did not make any statistical inference from these replicates. For biochemical or metabolomic experiment, a small sample size (2 or 3) was chosen due to the significant and consistent differences between groups.
Data exclusions Prior to SILAC quantification, peptides with a MASCOT score less than 25 or an isolation interference greater than 30 were excluded due to the uncertainty of their sequences. The isolation interference-based criterion has been established by Sandberg et al. (J. Proteomics, 2014, 96, pp. 134-44). We further arbitrarily excluded proteins identified by only one unique peptide or by 2 or more unique peptides only once out of three biological replicates for the lack of reliability.
In rare occasions, autosampler malfunction during LC-MS analysis of metabolomic samples may give rise to datasets with abnormally high signals for all internal standards. To avoid ion suppression caused by overload, such datasets are excluded and same samples are re-analyzed on the same instrument to provide substitutes.
Replication
As described above, we replicated all biochemical and metabolite-profiling experiments. All replicate experiments are successful.
Randomization This study does not involve subjects that require randomization.
Blinding
This study does not involve procedures that require blinding.
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